Gleyne Biagini - Academia.edu (original) (raw)
Uploads
Papers by Gleyne Biagini
Diabetes Research and Clinical Practice, 2000
Diabetes Research and Clinical Practice, 2000
Biology of Blood and Marrow Transplantation, 2009
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%)... more Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and event free survival (EFS) were 66% and 50% respectively. When survival was evaluated by the interval between the 1 st and 2 nd SCT: \ 6 months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55% and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005). With intervals of \ 12 months (26 pts) and $ 12 months (25 pts), the 10-year OS was 64% and 70% for the 2 cohorts respectively (P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts respectively (P 5 0.2). When survival was evaluated by underlying disease, the 10-year OS was 59%, 75% and 59% for pts with NMHD, IMD and leukemia respectively (P 5 0.3), and the 10-year EFS was 55%, 50%, and 59% (P 5 0.5) for the same groups respectively.
Biology of Blood and Marrow Transplantation, 2009
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%)... more Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and event free survival (EFS) were 66% and 50% respectively. When survival was evaluated by the interval between the 1 st and 2 nd SCT: \ 6 months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55% and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005). With intervals of \ 12 months (26 pts) and $ 12 months (25 pts), the 10-year OS was 64% and 70% for the 2 cohorts respectively (P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts respectively (P 5 0.2). When survival was evaluated by underlying disease, the 10-year OS was 59%, 75% and 59% for pts with NMHD, IMD and leukemia respectively (P 5 0.3), and the 10-year EFS was 55%, 50%, and 59% (P 5 0.5) for the same groups respectively.
Arquivos Brasileiros de Endocrinologia & Metabologia, 2005
A rabdomiólise tem sido motivo de publicação na literatura médica há mais de 50 anos. Nas últimas... more A rabdomiólise tem sido motivo de publicação na literatura médica há mais de 50 anos. Nas últimas décadas, com o advento das estatinas, usadas na prevenção primária e secundária da doença cardiovascular, este assunto volta como importante complicação, muitas vezes fatal, do uso desta classe de drogas. A rabdomiólise associada ao uso das estatinas ocorre principalmente devido a associações medicamentosas. A seguir, descreveremos um caso de uma paciente em uso de altas doses de Sinvastatina, devido à doença aterosclerótica difusa, que desenvolveu quadro compatível com rabdomiólise resultando em óbito. (Arq Bras Endocrinol Metab 2005;49/4:604-609)
Arquivos Brasileiros de Endocrinologia & Metabologia, 2008
Reviews in Endocrine and Metabolic Disorders, 2008
Diabetes Research and Clinical Practice, 2000
Diabetes Research and Clinical Practice, 2000
Biology of Blood and Marrow Transplantation, 2009
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%)... more Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and event free survival (EFS) were 66% and 50% respectively. When survival was evaluated by the interval between the 1 st and 2 nd SCT: \ 6 months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55% and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005). With intervals of \ 12 months (26 pts) and $ 12 months (25 pts), the 10-year OS was 64% and 70% for the 2 cohorts respectively (P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts respectively (P 5 0.2). When survival was evaluated by underlying disease, the 10-year OS was 59%, 75% and 59% for pts with NMHD, IMD and leukemia respectively (P 5 0.3), and the 10-year EFS was 55%, 50%, and 59% (P 5 0.5) for the same groups respectively.
Biology of Blood and Marrow Transplantation, 2009
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%)... more Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and event free survival (EFS) were 66% and 50% respectively. When survival was evaluated by the interval between the 1 st and 2 nd SCT: \ 6 months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55% and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005). With intervals of \ 12 months (26 pts) and $ 12 months (25 pts), the 10-year OS was 64% and 70% for the 2 cohorts respectively (P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts respectively (P 5 0.2). When survival was evaluated by underlying disease, the 10-year OS was 59%, 75% and 59% for pts with NMHD, IMD and leukemia respectively (P 5 0.3), and the 10-year EFS was 55%, 50%, and 59% (P 5 0.5) for the same groups respectively.
Arquivos Brasileiros de Endocrinologia & Metabologia, 2005
A rabdomiólise tem sido motivo de publicação na literatura médica há mais de 50 anos. Nas últimas... more A rabdomiólise tem sido motivo de publicação na literatura médica há mais de 50 anos. Nas últimas décadas, com o advento das estatinas, usadas na prevenção primária e secundária da doença cardiovascular, este assunto volta como importante complicação, muitas vezes fatal, do uso desta classe de drogas. A rabdomiólise associada ao uso das estatinas ocorre principalmente devido a associações medicamentosas. A seguir, descreveremos um caso de uma paciente em uso de altas doses de Sinvastatina, devido à doença aterosclerótica difusa, que desenvolveu quadro compatível com rabdomiólise resultando em óbito. (Arq Bras Endocrinol Metab 2005;49/4:604-609)
Arquivos Brasileiros de Endocrinologia & Metabologia, 2008
Reviews in Endocrine and Metabolic Disorders, 2008